REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy trial offers hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing whether adding a drug called pacritinib to a standard BTK inhibitor treatment is safe and might work better for people with mantle cell lymphoma that has come back or hasn't responded to prior therapy. The trial will enroll about 10 patients to c…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Gentle radiation could boost cancer drug power
Disease control Recruiting nowThis study is testing whether adding very low doses of radiation can help targeted drugs work better for people with mantle cell lymphoma that has returned or hasn't responded to previous treatments. About 80 patients will receive one or two days of low-dose radiation before star…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Double attack on cancer: engineered immune cells plus drug trial offers hope for tough lymphoma cases
Disease control Recruiting nowThis study tests whether combining two treatments works better against mantle cell lymphoma that has returned or resisted previous therapies. Researchers modify patients' own immune cells to target cancer and give them with the drug acalabrutinib. The trial aims to see if this co…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for lymphoma patients who failed CAR T-Cell treatment
Disease control Recruiting nowThis study tests whether a two-drug combination can help patients with mantle cell lymphoma whose cancer has returned or stopped responding after they received CAR T-cell therapy. The treatment uses glofitamab, which helps the immune system target cancer cells, along with obinutu…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New engineered immune cell therapy enters first human trials for aggressive blood cancers
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Faster drug Ramp-Up tested for tough blood cancers
Disease control Recruiting nowThis study is testing if a faster, higher dose increase of a new drug called sonrotoclax is safe and tolerable for patients with certain blood cancers. It is for adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), inclu…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for lymphoma patients who stop responding to standard drugs
Disease control Recruiting nowThis study is testing whether adding a targeted drug called loncastuximab tesirine after a short course of chemotherapy can help control relapsed mantle cell lymphoma in patients whose cancer stopped responding to or who couldn't tolerate BTKi drugs. About 49 patients will receiv…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC